Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 12 of 16
ValiRx's recent data well received
The company has two drugs in clinical trials, VAL 201 for prostate cancer, and VAL 401 for non-small cell lung cancer
ValiRx reformulates key drug as endometriosis treatment
The company has two drugs in clinical trials, VAL 201 for prostate cancer, and VAL 401 for non-small cell lung cancer
Proactive news highlights: ATTRAQT, Lombard Risk, Rare Earth, TyraTech and more...
European Wealth Grouphas acquired CIMCO Partners Management Limited, ATTRAQT Group reports a boost to sales, and Westminster Group's ferry heads off on its maiden voyage.
ValiRx’s lead compound continues to perform well
“Studies continue to show preliminary indications of VAL201 positively effecting subjects' disease profile”
Risers & Fallers: Aldermore, ASA Resource, Iofona, Petro Matad, Polemos, Vast Resources
Paternoster Resources has taken a big stake in Polemos, which has done wonders for the latter's share price, but not Paternoster's
Green-light received for start of ValiRx's lung cancer trial
All approvals have now been granted for the trial, which will be carried out in Tbilisi, Georgia
Proactive news highlights: 88 Energy, Caledonia Mining, FairFX, Minds + Machines and more...
Sareum Holdings plays down a recent report, Eurasia Mining agrees a refining contract and Minds + Machines is seeing exceptional growth.
ValiRx receives notification of patent grant allowance in New Zealand for VAL401
ValiSeek Limited, the joint venture between ValiRx and Tangent Reprofiling Limited has received notification of a New Zealand patent grant allowance.
Risers & fallers: Victoria, Management Resources Solutions, OptiBiotix Health, Orogen Gold, Clear Leisure, Man Group
Carpet seller Victoria's results caught the eye, with revenue and adjusted EBITDA double what they were in the previous year
ValiRx suspends use of loan facility with Bracknor
Having sold off its Finnish subsidiary earlier this month for €800,000 in cash, ValiRx has now terminated its convertible loan note facility with Bracknor.
ValiRx receives important sign-off for cancer trial
The AIM-listed company, which is working with Tangent Reprofiling, said it had received a positive opinion recommending the trial protocol.
Proactive news highlights: Bacanora, Leni Gas Cuba, Metal Tiger, Westminster Group and more...
Leni Gas Cub shareholders unanimously approve reverse take-over bid, StratMin Global Resources enters into a conditional sale and purchase agreement with Bass Metals and progress at Rare EarthSonora lithium project in Mexico is going well.